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We evaluated the effects of ACEA (selective cannabinoid (CB)1 receptor agonist), WIN 55,212-2 mesylate (WIN;
non-selective CB1 and CB2 receptor agonist) and N-palmitoylethanolamine (PEA; an endogenous fatty acid of
ethanolamide) in DBA/2 mice, a genetic model of reﬂex audiogenic epilepsy. PEA, ACEA or WIN intraperitoneal
(i.p.) administration decreased the severity of tonic-clonic seizures. We also studied the effects of PEA, WIN or
ACEA after co-administration with NIDA-41020 (CB1 receptor antagonist) or GW6471 (PPAR-α antagonist) and
compared the effects of WIN, ACEA and PEA in order to clarify their mechanisms of action. PEA has antic-
onvulsant features in DBA/2 mice mainly through PPAR-α and likely indirectly on CB1 receptors, whereas ACEA
and WIN act through CB1 receptors. The co-administration of ineffective doses of ACEA, PEA and WIN with
some antiepileptic drugs (AEDs) was examined in order to identify potential pharmacological interactions in
DBA/2 mice. We found that PEA, ACEA and WIN co-administration potentiated the efﬁcacy of carbamazepine,
diazepam, felbamate, gabapentin, phenobarbital, topiramate and valproate and PEA only also that of oxcar-
bazepine and lamotrigine whereas, their co-administration with levetiracetam and phenytoin did not have
effects. PEA, ACEA or WIN administration did not signiﬁcantly inﬂuence the total plasma and brain levels of
AEDs; therefore, it can be concluded that the observed potentiation was only of pharmacodynamic nature. In
conclusion, PEA, ACEA and WIN show anticonvulsant effects in DBA/2 mice and potentiate the effects several
AEDs suggesting a possible therapeutic relevance of these drugs and their mechanisms of action.
& 2016 Published by Elsevier B.V.1. Introduction
The endocannabinoid system has been demonstrated to play a
protective role in many central nervous system disorders including
epilepsy (Friedman and Devinsky, 2015; Gofﬁn et al., 2011; Leo
et al., 2016; Mattace Raso et al., 2014). It has been shown that both
some natural cannabinoids (especially, Δ9-tetrahydrocannabinol
and cannabidiol) and cannabinoid receptor agonists possess dif-
ferent anticonvulsant effects in several animal models of epilepsy
also acting through non cannabinoid receptors (Devinsky et al.,
2014; Hill et al., 2012; Jones et al., 2011). Different studies in-
dicated that the endogenous cannabinoid ligands anandamide
(AEA) and 2-arachidonylglycerol (2-AG) and the related non-cannabinoid ligand N-palmitoylethanolamine (PEA; an en-
dogenous bioactive fatty acid amide) have anticonvulsant prop-
erties in numerous in vitro and in vivo models (Citraro et al.,
2013a, 2013b; Lambert et al., 2001; Sheerin et al., 2004; Wallace
et al., 2003, 2002); in agreement, (R)-(þ)-[2,3-dihydro-5-methyl-
3-(4-morpholinyl-methyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1
naphthalenyl-methanone mesylate (WIN 55,212-2 mesylate, a
non-selective CB1/CB2 receptor agonist) and arachidonyl-2-chlor-
oethylamide (ACEA, a selective cannabinoid CB1 receptor agonist)
exerted anticonvulsant properties in several animal models of
epilepsy (Citraro et al., 2013a; Kozan et al., 2009; Shafaroodi et al.,
2013; Vilela et al., 2013; Wallace et al., 2003, 2002). PEA, an en-
dogenous fatty acid amide analogue of the endocannabinoid AEA,
produced on-demand within the lipid bilayer (Costa et al., 2008;
Petrosino et al., 2010) plays a crucial role in the regulation of
several pathophysiological processes, such as pain, inﬂammation,
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2013b; D’Agostino et al., 2012; Lambert et al., 2002; Mattace Raso
et al., 2014; Re et al., 2007). In particular, PEA has protective effects
both against maximal electroshock seizures (MES) and tonus in
the pentylentetrazole (PTZ) model of seizures (Lambert et al.,
2001). Moreover, it has also been observed that a pretreatment
with PEA increased the latency to seizures’ onset as well as de-
creased the duration of PTZ-induced seizures (Aghaei et al., 2015).
PEA also increased the latency to clonus in the kindling amygda-
loid model without, however, affecting duration of clonus and
after discharge (Sheerin et al., 2004). Finally, the anticonvulsant
effects of PEA have also been reported in a genetic absence epi-
lepsy model (Citraro et al., 2013b). Several mechanisms have been
proposed to explain the effects of PEA (Petrosino et al., 2010); to
date it is widely recognized that PEA does not bind directly to CB1/
CB2 receptors, whereas its pharmacological effects are mainly
mediated by activation of peroxisome proliferator-activated re-
ceptor (PPAR-α) (Di Cesare Mannelli et al., 2013; Hansen, 2010; Lo
Verme et al., 2005; O’Sullivan and Kendall, 2010; Raso et al., 2011;
Sugiura et al., 2000; Howlett et al., 2004). It has been recognized
that WIN potentiates the anticonvulsant activity of diazepam,
carbamazepine, phenytoin, phenobarbital, lamotrigine, pregabalin,
topiramate and valproate in the MES model (Luszczki et al., 2011b,
2013; Naderi et al., 2008); it also enhances the anticonvulsant
activity of ethosuximide, phenobarbital and valproate in the
mouse PTZ-induced seizures model (Luszczki et al., 2011a). ACEA
increased the anticonvulsant effects of valproate and pheno-
barbital (Andres-Mach et al., 2012; Luszczki et al., 2006; Luszczki
et al., 2010). It has been described that PEA might potentiate the
effect of AEA on CBRs and/or vanilloid receptor 1 (TRPV1) (Costa
et al., 2008; De Petrocellis et al., 2001; Ho et al., 2008). In
certain situations (i.e. after repeated treatments), PEA reduces AEA
hydrolysis employing fatty acid amide hydrolase (FAAH) (Ben-
Shabat et al., 1998; Di Marzo et al., 2001; Lambert and Di Marzo,
1999). Nevertheless, in WAG/Rij rats (an animal model of absence
epilepsy), we showed that PEA exerts anticonvulsant effects
mainly acting on PPAR-α receptor and only indirectly acting on
CBRs (Citraro et al., 2013b).
Based on this evidence, we have investigated the antic-
onvulsant mechanisms of WIN, ACEA and PEA and determined
their interaction with some AEDs (i.e. carbamazepine, diazepam,
felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine,
phenytoin, phenobarbital, topiramate and valproate) against
audiogenic seizures in the DBA/2 mouse, an experimental model of
audiogenic seizures (Citraro et al., 2011; De Sarro et al., 2015;
Donato Di Paola et al., 2007). Finally, we have also detected free
plasma and total brain concentrations of some AEDs in order to
ascertain any pharmacokinetic contribution to the observed in-
teractions between tested drugs.2. Materials and methods
2.1. Animals
Male DBA/2 mice weighing 8–12 g (22–26 days old) or 20–28 g
(48–56 days old) were used. Mice were purchased from Harlan
Italy srl (Correzzana, Milan, Italy), housed in groups and kept un-
der controlled conditions of humidity (6075%) and temperature
(2172 °C), with a reversed light/dark (12/12 h) cycle (light on at
19.00). Mice were allowed free access to standard laboratory chow
and tap water until the time of experiments. Procedures involving
animals and their care were performed in agreement with inter-
national and national law and policies (EU Directive 2010/63/EU
for animal experiments, ARRIVE guidelines and the Basel de-
claration including the 3 R concept). All efforts were made tominimize animal suffering and to use only the number of animals
necessary to have reliable scientiﬁc data.
2.2. Drugs
Felbamate (Schering Plough, Milano, Italy), carbamazepine and
oxcarbazepine (Novartis, Basel, Switzerland) and diazepam (Hoff-
man La Roche, Basel, Switzerland) were dissolved in a 1% solution
of Tween 80. Gabapentin (Sigma-Aldrich, Milan, Italy), levetir-
acetam (UCB Pharma, Braine-l’Alleud, Belgium), valproate (Mg2þ
salt; Sigma Tau, Pomezia, Italy), phenobarbital (Naþ salt; Sigma-
Aldrich, Milan, Italy), lamotrigine (Glaxo-Wellcome, Verona, Italy),
phenytoin (Naþ salt; Sigma-Aldrich, Milan, Italy) and topiramate
(personal gift from Dr. R.P. Shank; Johnson & Johnson Pharma-
ceutical Research & Development LCC, USA) were dissolved in 0.9%
sterile saline. N-palmitoylethanolamine (PEA, Sigma-Aldrich,
Milan, Italy), (R)-(þ)-[2,3-dihydro-5-methyl-3-(4-morpholi-
nylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1 naphthale-
nyl-methanone mesylate (WIN 55,212-2, Sigma-Aldrich, Milan,
Italy), arachidonyl-2-cyclopropylamide (ACEA, Tocris Bioscience,
Bristol, UK) and GW6471, a PPAR-α antagonist (Sigma-Aldrich,
Milan, Italy) were suspended in a 5% solution of Tween 80, 5%
polyethylene glycol (PEG) and in 90% sterile saline before i.p. ad-
ministration. 1-(2,4-Dichlorophenyl)-5-(4-methoxyphenyl)-4-me-
thyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide (NIDA-41020;
Sigma-Aldrich, Milan, Italy) was dissolved in a minimum amount
of dimethyl sulfoxide (DMSO); the ﬁnal volume was made up with
sterile saline before i.p. administration. All drugs were adminis-
tered i.p. at a volume of 0.1 ml/10 g of body weight. Control ani-
mals received equivalent volumes of the vehicle at the respective
times before the test as previously described (Russo et al., 2013).
2.3. Experimental design
DBA/2 mice were treated with: PEA (5–40 mg/kg, i.p.) 30, 60, 90
or 120 min before auditory stimulation; ACEA (0.5–30 mg/kg; i.p.)
30, 60 or 90 min before auditory stimulation; WIN (2.5–60 mg/kg;
i.p.) 10, 20 or 30 min before auditory stimulation; NIDA-41020
(0.5–2 mg/kg; i.p.) 45 min before auditory stimulation and
GW64721 intracerebroventricularly (i.c.v.) (0.5–4 μg/mouse) or
vehicle 30 min before auditory stimulation. The different times
and route of drugs administration were chosen according to pre-
viously published articles or personal pilot studies (Andres-Mach
et al., 2012; Citraro et al., 2013a, 2013b; Payandemehr et al., 2015).
AEDs were administered according to previously published studies
(see Results sections) (De Sarro et al., 2000; De Sarro et al., 1998). Mice,
under ﬂuothane anesthesia, were injected (i.c.v.) in the left or right
lateral ventricle (coordinates 1 mm posterior and 1mm lateral to the
bregma; depth 2.4 mm) through a 5 ml Hamilton microsyringe ﬁtted
with a nylon cuff on the needle, as previously described (De Sarro
et al., 2004). Sound stimulation (12–16 kHz; 109 dB) was applied for
1 min or until tonic extension occurred (Sarro et al., 2012).
2.4. Determination of plasma and brain levels of AEDs and effects on
motor coordination
DBA/2 mice were administered i.p. with vehicle or one com-
pound studied (PEA, ACEA, WIN, NIDA-41020 or GW6471) plus one
AED before audiogenic test. Behavioral and pharmacokinetic studies
were carried out under the same protocol (i.e. timing and dosing).
Drug level determination was performed by HPLC or im-
munoenzymatic assay in older mice (see Section 2.1) in order to
avoid difﬁculties in blood sampling, as previously described (Russo
et al., 2013). No pharmacokinetic changes were described between
21–26 and 48–56 days old mice (De Sarro et al., 2002; Sarro et al.,
2012). Rotarod test (U. Basile, Comerio, Varese, Italy) was carried out
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vestigation alone or in combination in order to determine their TD50
values (795% conﬁdence limits) by the method of Litchﬁeld and
Wilcoxon (1949), as previously reported (Russo et al., 2013).
2.5. Statistical analysis
Groups of control and drug-treated mice were statistical ana-
lyzed by Fisher's exact probability test or analysis of variance (AN-
OVA) and Dunnett's test whereas ED50 or TD50 values were calcu-
lated and statistically analyzed using the method of Litchﬁeld and
Wilcoxon as previously reported (Russo et al., 2013). The percent
occurrence of seizure phases of the administered compounds and
the dose-response curves were close-ﬁtting using linear regression
method. The lines of best ﬁt of AEDs plus vehicle or one cannabi-
noid were compared using a χ2-test, as previously described De
Sarro et al. (2012). The plasma levels of the studied compounds are
expressed as means7S.E.M. of at least eight determinations and
Student's t-test was performed for statistical comparison. Pr0.05Fig. 1. Dose-response curves of the anticonvulsant effects of PEA (5–40 mg/kg) 60 min afte
after PEA) and NIDA-41020 (1 mg/kg, i.p.; 15 min after PEA). Abscissa shows the log dosewas considered statistically signiﬁcant. The statistical software used
was GraphPad Prisma 6.0 (La Jolla, CA, USA).3. Results
3.1. Effects of PEA, ACEA and WIN against audiogenic seizures in
DBA/2 mice
Administration of vehicles had no effects on all phases of audio-
genic seizures (data not shown). The effects of PEA, ACEA and WIN
were studied at different times after administration, on different
parameters and various doses (Section 2.2). PEA (5–40 mg/kg), ACEA
(0.5–30 mg/kg) and WIN (5–60 mg/kg) administered i.p. reduced the
severity of tonic and clonic phases of audiogenic seizures in DBA/2
mice in a dose-dependent manner (Figs. 1–3); the obtained ED50
values (795% conﬁdence limits) for each compound are reported in
Table 1. ACEA and PEA were also effective against the wild running
phase of the audiogenic seizures (Table 1, Figs. 1 and 2) whereas,r i.p administration alone or in combination with GW6471 (2 μg/mouse, i.c.v.; 30 min
s, ordinate shows (A) percentage of clonic seizures, (B) percentage of tonic seizures.
Fig. 2. Dose-response curves of the anticonvulsant effects of ACEA (0.5–30 mg/kg) 60 min after i.p administration alone or in combinationwith GW6471 (2 μg/mouse, i.c.v.; 30 min
after ACEA) and NIDA-41020 (1 mg/kg, i.p.; 15 min after ACEA). Abscissa shows the log doses, ordinate shows (A) percentage of clonic seizures, (B) percentage of tonic seizures.
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to 60 mg/kg (Table 1 and Fig. 3). The rank order of potency measured
by the lowest ED50 values (expressed in μmol/kg) for tonus and
clonus is: ACEA tonus (18.77 μmol/kg) clonus (25.63 μmol/kg)4PEA
tonus (34.46 μmol/kg) clonus (38.88 μmol/kg)4WIN tonus (66.73
μmol/kg) clonus (84.64 μmol/kg). The anticonvulsant properties of
these drugs had a maximum effect 90 min after administration of
PEA, 60 min after ACEA and 20 min after WIN (Table 1).
NIDA-41020 (0.5–2 mg/kg, i.p.) and GW6471 (0.5–4 μg/mouse,
i.c.v.) had any anticonvulsant effects against the wild running,
clonic or tonic phase of audiogenic seizures in DBA/2 mice when
administered alone (data not shown).
Since PEA (5 mg/kg i.p.), ACEA (2 mg/kg) and WIN (5 mg/kg i.p.)
did not signiﬁcantly affect reﬂex seizures per se as it was also
observed in previous studies (Citraro et al., 2013a; Luszczki et al.,
2011b, 2013); these doses were selected for the following section
of the present experimental protocol to be tested in co-adminis-
tration with AEDs (see Section 2.3). The doses of these three drugs
used did not induce any locomotor impairment as measured in the
rotarod test as well as did not modify body temperature (data not
shown; see Section 2.3).3.2. Effects of GW6471 and NIDA-41020 on the anticonvulsant ef-
fects of PEA, WIN and ACEA in DBA/2 mice
GW6471 (2 μg/mouse, i.c.v.) and NIDA-41020 (1 mg/kg, i.p.)
were able to signiﬁcantly antagonize the anticonvulsant properties
of PEA shifting to the right its dose-response curves, whereas
NIDA-41020 only (1 mg/kg, i.p.), but not GW6471 (2 μg/mouse, i.c.
v.), was able to signiﬁcantly reduce the anticonvulsant properties
of both ACEA and WIN (Figs. 1–3; Table 1).
3.3. Effects of PEA, WIN and ACEA upon the anticonvulsant activity of
conventional AEDs versus audiogenic seizures in DBA/2 mice
All AEDs studied showed anticonvulsant effectiveness against
audiogenic seizure of DBA/2mice (Table 2), as previously reported (De
Sarro et al., 2015). PEA's effects upon the activity of the AEDs on reﬂex
audiogenic seizures were different depending on the AED tested.
PEA pretreatment (5 mg/kg, i.p.) produces a consistent shift to the
left of the dose-response curves for some AEDs; a signiﬁcant decrease
of ED50 values against clonus and tonus was found for all drug com-
binations except levetiracetam and clonus for phenytoin (Table 2).
Fig. 3. Dose-response curves of the anticonvulsant effects of WIN (2.5–60mg/kg) 20 min after i.p administration alone or in combination with GW6471 (2 μg/mouse, i.c.v.; 10 min
before WIN) and NIDA-41020 (1 mg/kg, i.p.; 25 min before WIN). Abscissa shows the log doses, ordinate shows (A) percentage of clonic seizures, (B) percentage of tonic seizures.
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consistent shift to the left of the dose-response curves and a sig-
niﬁcant reduction (P at leasto0.05) of ED50 values for clonus and/or
tonus of some AEDs (Table 2). In particular, combined treatment of
AEDs with ACEA (2 mg/kg, i.p.) signiﬁcantly reduced all ED50 values
for clonus except those of lamotrigine, levetiracetam, oxcarbaze-
pine, phenytoin and topiramate and for tonus also for oxcarbaze-
pine. Similarly, WIN (5 mg/kg, i.p.) signiﬁcantly reduced ED50 values
for both clonus and tonus of all AEDs except levetiracetam, oxcar-
bazepine, and phenytoin. Therefore, comparing WIN and ACEA the
main difference was the ability of WIN to potentiate at this dose of
also lamotrigine and topiramate for clonus only (Table 2).
3.4. Effects of NIDA 41020 and GW6471 upon the anticonvulsant
activity of AEDs versus audiogenic seizures in DBA/2 mice
NIDA-41020 (1 mg/kg i.p.; 45 min before auditory stimulation)
or GW6471 (2 μg/mouse i.c.v.; 30 min before auditory stimulation)
were unable to signiﬁcantly modify the dose-response curves for all
AEDs studied (Table 2). All dose-response curves of wild running
were parallel with the exception of diazepam plus NIDA-41020,
levetiracetam plus GW6471, phenytoin plus WIN, topiramate plusGW6471 or valproate plus NIDA-41020 (data not shown). Indeed, all
dose-response curves of clonus were parallel with the exception of
carbamazepine plus GW6471, levetiracetam plus ACEA, valproate
plus GW6471.
3.5. Effects of PEA, WIN and ACEA upon the motor impairment in-
duced by AEDs
All AEDs, used at doses equal to their ED50 values against the
clonic phase of the audiogenic seizures, did not modify motor
performance of DBA/2 mice on the rotarod test (Sarro et al., 2012).
Higher doses were required to induce motor deﬁcit. TD50 values
were signiﬁcantly reduced by co-administration of PEA with all
AEDs with the exception of carbamazepine and levetiracetam. The
concomitant treatment of WIN or ACEAwith AEDs resulted usually
in an increase of motor impairment. TD50 values were signiﬁcantly
decreased by WIN and ACEA in combination with all AEDs with
the exceptions of carbamazepine, levetiracetam, and phenytoin for
WIN and carbamazepine, levetiracetam and oxcarbazepine for
ACEA. Although TD50 was lowered, the therapeutic index (TI) of all
AEDs co-administered with PEA, ACEA or WIN was generally
comparable to AEDs alone if not higher (Table 3).
Table 1
ED50 values (795% conﬁdence limits) for PEA, WIN, ACEA, alone or co-administered with NIDA 41020 or GW6471 on audiogenic seizures in DBA/2 mice at different time
points after drug administration.
Treatment drug Seizure phase
(Time) Wild running Clonus Tonus
PEA (30 min) 47.0 (34.58–63.88) 31.23 (26.23–37.19) 18.23 (13.38–24.83)
PEA (60 min) 27.21 (21.83–33.93) 19.41 (14.61–25.65) 11.53 (8.14–16.34)
PEA (90 min) 22.94 (17.23–30.54) 11.80 (7.63–18.26) 10.46 (6.38–17.16)
PEA (120 min) 29.04 (23.24–36.3) 21.35 (15.12–30.14) 12.04 (8.10–17.90)
NIDA 41020 (45 min)þPEA (60 min) 36.96 (26.88–50.82) 26.48 (21.36–32.84) 24.88 (17.87–34.65)aa
NIDA 41020 (45 min)þPEA (90 min) 29.08 (20.33–41.58) 20.49 (15.05–27.89)a 17.35 (10.75–27.99)a
GW6471 (30 min)þPEA (60 min) 37.09 (32.49–42.35)a 30.01 (25.73–30.17)a 21.32 (15.17–29.97)a
GW6471 (30 min)þPEA (90 min) 33.94 (26.13–44.07) 24.36 (17.71–33.52)aa 18.77 (12.66–27.84)a
WIN (10 min) NM 56.84 (32.30–65.05) 47.32 (26.56–84.30)
WIN (20 min) 51.51 (40.48–65.54) 36.10 (22.71–57.39) 28.46 (19.18–42.23)
WIN (30 min) 58.64 (44.82–76.74) 47.32 (26.56–84.30) 33.96 (25.88–44.56)
NIDA 41020 (45 min)þWIN (20 min) 75.62 (55.78–102.53)a 65.66 (49.08–80.42)a 51.77 (33.79–79.34)a
GW6471 (30 min)þWIN (20 min) 57.05 (40.48–80.42) 38.03 (31.01–46.63) 28.88 (19.61–40.76)
ACEA (30 min) 23.86 (14.6–39.0) 19.97 (14.29–27.91) 11.22 (9.03–13.94)
ACEA (60 min) 12.68 (9.71–16.56) 9.38 (7.48–11.77) 6.87 (4.71–10.03)
ACEA (90 min) 19.97 (14.29–27.91) 16.96 (12.15–23.67) 10.45 (8.15–13.41)
NIDA 41020 (45 min)þACEA (60 min) 28.88 (17.87–34.65)aa 18.33 (12.33–27.28)a 12.08 (6.92–21.09)a
GW6471 (30 min)þACEA (60 min) 13.74 (8.56–22.03) 9.08 (6.39–12.90) 6.82 (4.47–10.40)
All data are expressed as mg/kg and were calculated according to the method of Litchﬁeld and Wilcoxon (1949). NM¼not measurable up to the dose of 60 mg/kg. Signiﬁcant
differences among concurrent groups are marked by aPo0.05 and aaPo0.01.
Table 2
ED50 values (795% conﬁdence limits) for vehicle plus the antiepileptic drugs or in combination with PEA (5 mg/kg, i.p.), NIDA 41020 (1 mg/kg, i.p.), WIN (5 mg/kg, i.p.), ACEA
(2 mg/kg, i.p.) or GW64716 (2 μg/mouse i.c.v.) against audiogenic seizures in DBA/2 mice.
Drug þVehicle þPEA þNIDA 41020 þWIN þACEA þGW6471
Wild running Carbamazepine 10.6 (8.1–13.8) 7.8 (6.5–9.4)a 10.2 (8.013.0) 8.1 (6.3–10.4)a 7.8 (6.1–9.97)a 10.4 (8.2–13.2)
Diazepam 0.49 (0.34–0.71) 0.31 (0.21–0.46)a 0.49 (0.320.75) 0.35 (0.27–0.45)a 0.33 (0.22–0.44)a 0.46 (0.32–0.66)
Felbamate 114.6 (92–142.7) 82 (64–105.1)a 119 (95149.1) 85 (62–116)a 87 (61–124)a 108 (88–132.5)
Gabapentin 38 (16–51) 22.4 (17.1–29.3)aa 38.2 (19.375.6) 23.8 (18.2–31.1)aa 23.2 (17.1–31.5)aa 37.2 (24.1–57.42)
Lamotrigine 6.1 (4.6–8.1) 3.6 (2.8–4.63)aa 6.4 (4.98.36) 3.9 (3.2–4.7)a 3.7 (3.1–4.4)a 5.9 (4.3–8.1)
Levetiracetam 15.4 (12.2–19.5) 13.2 (11.2–15.6) 15.8 (12.619.8) 14.8 (11.718.7) 14.4 (12.816.2) 15.6 (11.8–20.6)
Oxcarbazepine 11.4 (9.7–13.3) 7.4 (6.2–8.83)a 11.8 (9.814.2) 8.9 (7.510.6) 8.7 (7.4–10.2) 12.4 (9.6–16.0)
Phenobarbital 7.1 (5.6–9.0) 4.19 (3.6–4.88)aa 6.5 (5.4–7.8) 5.47 (4.5–6.6) 5.8 (4.6–7.3) 6.5 (4.8–8.8)
Phenytoin 4.3 (3.1–6.0) 3.7 (2.4–5.7) 4.1 (3.0–5.8) 4.3 (2.9–6.4) 3.9 (2.6–5.8) 4.4 (3.1–6.25)
Topiramate 22.9 (15.8–33.9) 12.1 (10.2–14.4)aa 23.4 (18.4–29.7) 14.3 (11.817.3)aa 14.6 (12.1–17.6)aa 23.4 (16.233.8)
Valproate 84 (63–114) 51 (37–70.3)aa 79 (65–96.0) 52.5 (38–72.5)aa 54 (38–76.7)a 80.2 (59.1–108.8)
Clonus Carbamazepine 4.4 (3.6–5.4) 2.7 (2.0–3.6)aa 4.6 (3.75.7) 3.1 (1.9–5.1)a 2.9 (2.1–4.0)aa 3.7 (2.5–5.6)
Diazepam 0.28 (0.2–0.39) 0.18 (0.13–0.25)aa 0.29 (0.21–0.40) 0.19 (0.14–0.25)aa 0.19 (0.14–0.26)aa 0.26 (0.20–0.34)
Felbamate 48.8 (35–67) 30.2 (24.8–36.8)aa 49.8 (39.6–62.6) 32 (26–39.4)aa 34.6 (26.9–44.5)a 45 (30–69)
Gabapentin 20.3 (13.7–30.2) 12.4 (9.6–16.02)aa 20.9 (15.827.65) 13.3 (10.3–17.2)aa 13.5 (10.7–17.0)aa 21.1 (16.1–26.3)
Lamotrigine 3.5 (2.4–5.1) 2.1 (1.6–2.7)aa 3.8 (2.65.55) 2.2 (1.5–3.2)a 2.9 (2.3–3.65) 3.9 (2.6–5.8)
Levetiracetam 9.8 (7.2–13.2) 9.5 (7.4–12.2) 9.9 (7.812.6) 8.8 (6.8–11.4) 9.6 (7.3–12.6) 9.6 (7.1–13.5)
Oxcarbazepine 4.2 (3.0–5.88) 2.7 (2.0–3.6)a 4.4 (3.4–5.69) 3.7 (2.6–6.53) 3.9 (2.8–5.4) 4.1 (2.9–5.8)
Phenobarbital 3.4 (2.3–5.0) 2.0 (1.5–2.67)aa 3.3 (2.1–5.19) 2.1 (1.7–2.6)aa 2.2 (1.8–2.69)a 3.3 (2.4–4.54)
Phenytoin 2.5 (1.8–3.5) 2.1 (1.7–2.6) 2.3 (1.9–2.8) 2.2 (1.8–2.7) 2.2 (1.8–2.7) 2.6 (1.9–3.6)
Topiramate 12.1 (6.9–21.2) 6.5 (5.5–7.68)aa 12.4 (7.7–19.9) 8.96 (6.34–13.57)a 10.1 (8.0–12.8) 12.1 (8.0–18.3)
Valproate 43 (33–56) 22.7 (18.4–28.0)aa 41.7 (26.2–66.4) 25.9 (20.2–33.2)aa 25.3 (19.4–33.0)aa 44 (34–56.9)
Tonus Carbamazepine 3.0 (2.6–3.8) 1.7 (1.3–2.22)aa 3.1 (2.7–3.56) 2.1 (1.6–2.76)a 1.9 (1.45–2.49)aa 3.1 (2.7–3.56)
Diazepam 0.24 (0.15–0.39) 0.15 (0.11–0.20)aa 0.22 (0.18–0.27) 0.16 (0.120.21)aa 0.17 (0.12–0.24)a 0.24 (0.150.39)
Felbamate 23.1 (18.15–9.4) 14.2 (9.8–20.6)aa 23.8 (18.3–30.9) 17.8 (14.2–22.4)a 16.1 (12.221.2)aa 24.2 (18.6–31.5)
Gabapentin 13.9 (8.7–22.3) 6.5 (4.9–8.6)aa 13.3 (10.9–16.2) 7.2 (5.469.26)aa 6.8 (5.618.26)aa 14.1 (12.4915.92)
Lamotrigine 1.1 (0.7–1.8) 0.6 (0.4–0.9)aa 1.21 (0.9–1.63) 0.8 (0.5–1.3)a 0.9 (0.7–1.1) 1.2 (0.9–1.6)
Levetiracetam 7.9 (5.9–10.6) 7.3 (5.8–9.2) 7.8 (6.1–9.97) 7.5 (6.3–8.9) 7.6 (6.3–9.2) 8.1 (6.5–10.4)
Oxcarbazepine 3.2 (2.7–3.79) 2.0 (1.4–2.86)aa 3.0 (2.4–3.75) 2.5 (1.8–3.5) 2.2 (1.6–3.0)* 3.2 (2.3–4.5)
Phenobarbital 2.4 (1.7–3.4) 1.3 (0.9–1.88)aa 2.2 (1.8–2.7) 1.5 (1.2–1.88)aa 1.5 (1.1–2.05)aa 2.2 (1.8–2.7)
Phenytoin 2.0 (1.6–2.5) 1.4 (1.1–1.8)a 1.9 (1.5–2.41) 1.6 (1.2–2.13) 1.7 (1.4–2.1) 2.1 (1.6–2.76)
Topiramate 6.12 (4.8–9.18) 3.25 (2.58–4.09)aa 6.4 (5.2–7.88) 3.94 (2.42–6.41)aa 3.84 (2.78–5.3)aa 6.1 (4.6–8.1)
Valproate 31 (22–43) 16.4 (12.5–21.5)aa 30.2 (20.4–44.7) 18.2 (14.7–22.5)aa 17.6 (14.2–21.8)aa 31 (21–46)
All data are expressed as mg/kg and were calculated according to the method of Litchﬁeld and Wilcoxon (1949). Vehicle, PEA 90 min , WIN 20 min , ACEA 60 min or GW6471
30 min before rotarod test, respectively. AEDs: lamotrigine, oxcarbazepine and gabapentin 45 min , carbamazepine, diazepam, levetiracetam and felbamate 60 min , phe-
nobarbital and valproate 60 min , phenytoin 120 min , topiramate 90 min before auditory stimulation. Signiﬁcant differences among groups are marked by aPo0.05 and
aaPo0.01.
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Table 3
TD50 values (795% conﬁdence limits) for various antiepileptic drugs plus vehicle or in combination with PEA (5 mg/kg, i.p.), NIDA 41020 (1 mg/kg, i.p.), WIN (5 mg/kg, i.p.), ACEA (2 mg/kg, i.p.) or GW64716 (2 μg/mouse i.c.v.) in the
rotarod test.
Treatment TD50 TI Treatment TD50 TI
CarbamazepineþVehicle 46.5 (37.9–57) 10.5 LamotrigineþVehicle 81 (55–118) 23.1
CarbamazepineþPEA 39.8 (28.7–55.2) 14.7 LamotrigineþPEA 44.7 (34.9–57.2)aa 21.3
CarbamazepineþNIDA 41020 47.4 (36.3–61.2) 10.3 LamotrigineþNIDA 41020 79 (58–108) 20.8
CarbamazepineþWIN 38.0 (30.2–47.2) 12.3 LamotrigineþWIN 44.8 (35–57.3)aa 20.4
CarbamazepineþACEA 41.2 (34.1–49.8) 14.2 LamotrigineþACEA 43.4 (33–57.1)aa 15
CarbamazepineþGW64716 48.1 (36.4–64) 13 LamotrigineþGW64716 82.7 (63–109) 21.2
DiazepamþVehicle 3.8 (3.0–4.8) 13.5 PhenobarbitalþVehicle 139 (115–168) 40.9
DiazepamþPEA 2.4 (1.6–3.6)a 13.3 PhenobarbitalþPEA 97.7 (81–118)a 48.8
DiazepamþNIDA 41020 3.8 (2.8–5.2) 13.1 PhenobarbitalþNIDA 41020 135 (114–160) 40.9
DiazepamþWIN 2.2 (1.4–3.46)a 11.5 PhenobarbitalþWIN 88.7 (72–109.3)a 42.2
DiazepamþACEA 2.6 (1.8–4.8)a 13.7 PhenobarbitalþACEA 98 (78–123.1)a 44.5
DiazepamþGW64716 3.7 (2.8–4.9) 14.2 PhenobarbitalþGW64716 131.4 (103–167.6) 39.7
FelbamateþVehicle 816 (590–1024) 16.7 TopiramateþVehicle 162 (110–238.6) 13.4
FelbamateþPEA 582 (523–648)a 19.3 TopiramateþPEA 102.9 (89.3–118.6)aa 15.8
FelbamateþNIDA 41020 783 (581–1055) 15.8 TopiramateþNIDA 41020 154.4 (116–205) 13
FelbamateþWIN 532 (424–667)a 16.6 TopiramateþWIN 103.7 (82.5–130.4)aa 11.6
FelbamateþACEA 526 (431–642)a 15.2 TopiramateþACEA 116.5 (95.9–141.5)a 11.5
FelbamateþGW64716 776 (547–1101) 17.2 TopiramateþGW64716 158 (119–210) 13.1
GabapentinþVehicle 290.3 (218.3–386) 14.3 ValproateþVehicle 290 (240–251) 7.3
GabapentinþPEA 194 (138–273)a 15.6 ValproateþPEA 201.7 (182–223.6)a 8.9
GabapentinþNIDA 41020 261 (179–380.6) 12.5 ValproateþNIDA 41020 280.2 (229–343) 7.1
GabapentinþWIN 192 (148–249)a 14.4 ValproateþWIN 161.5 (137–190.3)aa 6.2
GabapentinþACEA 171 (119–246)a 12.7 ValproateþACEA 209.5 (177–247.9)a 8.3
GabapentinþGW64716 276 (187–407) 13.1 ValproateþGW64716 287(223–369.4) 6.5
OxcarbazepineþVehicle 60.9 (52.1–71.2) 19 LevetiracetamþVehicle 1601 (1334.2–1921.1) 163.4
OxcarbazepineþPEA 41.7 (33.5–51.8)a 20.8 LevetiracetamþPEA 1327 (1105.8–1592.4) 139.7
OxcarbazepineþNIDA 41020 56.8 (49.2–65.6) 18.9 LevetiracetamþNIDA 41020 1578 (1254–1985) 159.4
OxcarbazepineþWIN 41.5 (34.3–50.2)a 16.6 LevetiracetamþWIN 1254 (1019.5–1542.4) 142.5
OxcarbazepineþACEA 40.3 (32.8–49.5) 14.9 LevetiracetamþACEA 1512 (1239.3–1768) 157.5
OxcarbazepineþGW64716 57.2 (48.6–67.3) 17.9 LevetiracetamþGW64716 1586 (1306–1926) 165.2
PhenytoinþVehicle 48.3 (34.1–68.4) 19.3 All data are expressed as mg/kg and were calculated according to the method of Litchﬁeld and Wilcoxon (1949). Vehicle, PEA 90 min , WIN 20 min , ACEA 60 min or GW6471
30 min before rotarod test, respectively. AEDs: lamotrigine, oxcarbazepine and gabapentin 45 min , carbamazepine, diazepam, levetiracetam and felbamate 60 min , phe-
nobarbital and valproate 60 min , phenytoin 120 min , topiramate 90 min before rotarod test. TI¼therapeutic index, represents the ratio between TD50 and ED50 from the
clonic phase of audiogenic seizures. Signiﬁcant differences among groups are marked by aPo0.05 and aaPo0.01.
PhenytoinþPEA 37.2 (28.3–48.6)a 17.7
PhenytoinþNIDA 41020 48.1 (32.7–70.7) 20.9
PhenytoinþWIN 41.1 (30.5–55.4) 18.7
PhenytoinþACEA 33.2 (25.6–43.1)a 15.1
PhenytoinþGW64716 47.3 (34.2–65.4) 18.2
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concentrations of AEDs in DBA/2 mice
Plasma and brain levels of AEDs given alone or together with
PEA (5 mg/kg, i.p.), ACEA (2 mg/kg, i.p.), NIDA 41020 (1 mg/kg, i.p.;
only for plasma determination) or WIN (5 mg/kg, i.p.) are reported
in Tables 4 and 5. At the doses investigated both AEDs’ plasma and
brain concentrations were not signiﬁcantly altered by the admin-
istration of any of these drugs; however, PEA, WIN, NIDA and/or
ACEA slightly modiﬁed free plasma levels of felbamate, phenytoin,
phenobarbital (Table 4). Brain levels of AEDs were not signiﬁcantly
modiﬁed and slight not signiﬁcant modiﬁcation were observed for
carbamazepine, diazepam, felbamate, oxcarbazepine, phenytoin,
phenobarbital and valproate (Table 5).Ta
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.4. Discussion
The results of this study suggest that the endogenous non can-
nabimimetic compound PEA and the synthetic cannabinoids ACEA
and WIN, administered before auditory test, are able to prevent re-
ﬂex audiogenic seizures in DBA/2 mice, a widely investigated model
of audiogenic generalized seizures (De Sarro et al., 2015; Donato Di
Paola et al., 2007; Gitto et al., 2007; Italiano et al., 2016). While ef-
ﬁcacy against clonus and tonus was comparable for all three drugs;
ACEA was the most potent followed by PEA and then WIN and PEA
was the longer acting of the three. The second group of experiments
demonstrated that the anticonvulsant properties of PEA, ACEA and
WIN were antagonized by NIDA-41020 (a selective CB1 receptor an-
tagonist) and therefore supports the fact that these drugs directly or
indirectly exert their anticonvulsant action through the en-
docannabinoid system. Accordingly, the present results further sug-
gest that the activation on the cannabinoid system in the brain has
anticonvulsant effects and might contribute to enhance the antic-
onvulsant activity of AEDs used considering the pharmacodynamics
potentiation observed in this study. The anticonvulsant properties of
cannabinoid system activation might derive from their direct an-
tagonism or impairment of glutamate neurotransmission, which has
been suggested by some authors (Maier et al., 2012; Polissidis et al.,
2013; Ruehle et al., 2013; Sanchez-Blazquez et al., 2014). However,
other studies have shown that neuroprotection could be also medi-
ated by a modulation of GABAergic tone (Albayram et al., 2011; An-
tonucci et al., 2012; Blair et al., 2009; Karlocai et al., 2011).
Previously, some authors have demonstrated that WIN or ACEA
alone do not inﬂuence the threshold for electroconvulsions and
that both drugs, acutely administered, increase brain level of car-
bamazepine, phenobarbital and valproate and potentiate the an-
ticonvulsant effects of various AEDs without signiﬁcantly mod-
ifying plasma and brain levels (Luszczki et al., 2011a, 2011b, 2006,
2010, 2013; Luszczki and Florek-Luszczki, 2012).
The efﬁcacy of PEA to reduce seizures is consistent with several
reports demonstrating the antiseizure properties of this com-
pound against PTZ- and electroshock-induced convulsions in mice
(Aghaei et al., 2015; Lambert et al., 2001), against kindled amyg-
daloid seizures in rats (Sheerin et al., 2004) and absence seizures
in WAG/Rij rat (Citraro et al., 2013b). The microinjection of
GW6471 alone did not induce signiﬁcant modiﬁcation in the se-
verity of reﬂex seizures in DBA/2 mice, or inﬂuence ACEA and WIN
effects, while antagonized the anticonvulsant properties of PEA.
This suggests that PEA properties at PPAR-α receptors are involved
in the control of audiogenic seizures in DBA/2 mice. Furthermore,
NIDA-41020 antagonized the anticonvulsant effects of PEA, ACEA
and WIN; therefore, the above-described results show that PEA
plays an anticonvulsant role in DBA/2 mice acting on both CB1
receptors and PPAR-α, whereas ACEA and WIN act prevalently
through CB1 receptors.
Table 5
Inﬂuence of PEA, WIN or ACEA on brain levels of some antiepileptic compounds in DBA/2 mice.
Drug (time) (dose mg/kg) þVehicle þPEA þWIN þACEA
Carbamazepine (60 min) (15 mg/kg) 3.6570.49 4.6670.44 3.9270.42 3.9670.42
Diazepam (60 min) (5 mg/kg) 0.21470.018 0.28970.024 0.26470.021 0.27270.019
Felbamate (60 min) (100 mg/kg) 3.5770.39 3.7570.42 3.5970.34 3.6170.33
Gabapentin (45 min) (70 mg/kg) 9.871.5 9.971.5 9.971.4 9.971.3
Lamotrigine (45 min) (10 mg/kg) 1.570.18 1.6070.19 1.5870.18 1.5770.19
Levetiracetam (60 min) (100 mg/kg) 31.5274.54 31.8574.36 31.6874.26 31.5074.32
Oxcarbazepine (45 min) (15 mg/kg) 0.8070.15 0.8870.17 0.8670.16 0.8570.16
Phenytoin (120 min) (10 mg/kg) 1.5470.22 1.8970.20 1.6970.19 1.7170.20
Phenobarbital (60 min) (20 mg/kg) 9.0470.72 11.0970.74 10.7270.74 10.5570.77
Topiramate (90 min) (30 mg/kg) 4.4170.31 4.4870.25 4.4670.30 4.4770.29
Valproate (60 min) (200 mg/kg) 91.2977.89 108.3278.54 103.3878.36 102.6778.24
Drugs were administered i.p. Vehicle, PEA (5 mg/kg) 90 min before, WIN (5 mg/kg) 20 min before or ACEA (2 mg/kg) 60 minþ lamotrigine, oxcarbazepine and gabapentin
45 min, carbamazepine, diazepam, levetiracetam, felbamate, phenobarbital and valproate 60 min, phenytoin 120 min, topiramate 90 min before sampling. Values are means
(μg/ml) of at least eight determinations7S.E.M. Student's t-test was used for statistical analysis of the data. No signiﬁcant differences were observed.
R. Citraro et al. / European Journal of Pharmacology 791 (2016) 523–534 5314.1. Cannabinomimetic compounds and seizures
The anticonvulsant properties of CB1 receptors agonists in sev-
eral models, as above described, are likely linked to the ability of
this receptor to activate multiple secondary mechanisms of actions:
for instance ACEA and WIN by activation of CB1 receptors lead to a
decrease in cAMP production through activation of Gi proteins. This
effect is linked to an inhibition of protein kinase A (Bidaut-Russell
and Howlett, 1991). Moreover, in the brain, the inhibition of cAMP
pathway decreases intracellular Ca2þ load through voltage-acti-
vated N and P/Q type Ca2þ channels. This inhibition seems to be
responsible of a reduction of presynaptic neurotransmitter release
(Mackie et al., 1993). CB1 receptor activation also increases the
conductance of presynaptic A type (Hampson et al., 1995) and
G-protein-coupled inward rectifying Kþ channels (Mackie et al.,
1995). Moreover, CB1R are also involved in the reduction of gluta-
mate release both from spinal cord (Richardson et al., 1998) and
hippocampal neurons (Shen et al., 1996), as well as in the inhibition
of GABA reuptake in the globus pallidus. All these effects could be
responsible for their anticonvulsant features (Engler et al., 2006;
Lutz, 2004; Maneuf et al., 1996; Sieradzan et al., 2001). In particular,
it has been shown that CB1 receptors are found on the nerve
terminals of GABAergic interneurons localized in neocortex, hip-
pocampus and amygdala (Falenski et al., 2007; Freund et al., 2003)
and on the nerve terminals of excitatory amino acids localized in
cerebellum and striatum (Armstrong et al., 2009; Huang et al.,
2001; Marsicano and Lutz, 1999). All these mechanisms of antic-
onvulsant action associated with the activation of CB1 receptors
could be linked to the anticonvulsant properties against reﬂex sei-
zures in DBA/2 mice and for the increase of anticonvulsant activity
of AEDs observed in the present study (see below).
4.2. Interactions among AEDs, PEA and cannabinomimetics
The anticonvulsant effect of carbamazepine, diazepam, gaba-
pentin, felbamate, phenobarbital, and valproate against audiogenic
seizures was increased by the co-administration of all compounds
studied (PEA, WIN and ACEA) administered at doses that did not
inﬂuence the frequency of audiogenic seizures per se. At odds, the
potency of levetiracetam, oxcarbazepine, topiramate and phenytoin
was generally not signiﬁcantly increased by WIN and ACEA while
PEA appeared to have a broader spectrum of potentiation also im-
proving the effectiveness of more drugs in comparison to WIN and
ACEA. Antagonism at either CB1 or PPAR-α receptors was not able to
affect AEDs effects indicating that at least in this model their effects
are not mediated by any of these systems. The mechanisms causing
the pharmacological potentiation of AEDs seem to be based only on
pharmacodynamic interactions since no signiﬁcant alterations inAEDs plasma or brain concentrations were observed. Several me-
chanisms may be involved in the anticonvulsant potentiation ob-
served with PEA, ACEA and WIN. The favorable effects observed
might be categorized according to the mechanism of action pos-
sessed by AEDs. Considering their molecular mechanisms, it is
possible to hypothesize that ACEA, PEA andWIN might enhance the
anticonvulsant effect of gabapentin by interfering with inhibition of
P/Q-type and L-type high-voltage-activated calcium channels, and
enhanced the anticonvulsant activity of phenobarbital and diaze-
pam through a positive interaction with GABA neurotransmission
(De Sarro et al., 2002). However, it is not possible to exclude that
ACEA, PEA and WIN, used at different doses, could enhance the
anticonvulsant activity of AEDs through other mechanisms.
4.3. PEA and PPAR-α interactions
PEA has low afﬁnity for CB1 and CB2 receptors even if the CB2
antagonist SR144528 reverses some of its pharmacological proper-
ties (Calignano et al., 1998; Citraro et al., 2013b). It was reported that
PEA possesses effects that might not be correlated to the activation
of CBRs. Conversely, PEA's effects are currently suggested to be
mediated by the nuclear receptor PPAR-α (D’Agostino et al., 2007;
Lo Verme et al., 2005; Mattace Raso et al., 2014; Raso et al., 2011).
Evidence reported that PEA as well as its structural analogue
oleoylethanolamide (Fu et al., 2003) by activating on PPAR-α, are
able to decrease pain and inﬂammation (D’Agostino et al., 2007; Lo
Verme et al., 2005; O’Sullivan and Kendall, 2010; Re et al., 2007).
PPAR-α is mostly distributed in several peripheral organs (O'Sulli-
van and Kendall, 2010); however, it is also localized in some areas of
the nervous system (Kainu et al., 1994; Moreno et al., 2004). Fur-
thermore, PEA by activating on PPAR-α in microglial cells and hip-
pocampal neurons is able to exert neuroprotective properties (Koch
et al., 2011; Scuderi et al., 2012). Moreover, as demonstrated by
Sasso et al. (2010), administration of PEA increased pentobarbital
induced loss of righting reﬂex (LORR) duration in mice, enhancing
neurosteroidogenic pathway, and this effect disappears in PPAR-α
knockout mice. Based on this background and on the effects ob-
served in our experiments, it possible to conﬁrm that PPAR-α are
implicated in the anticonvulsant effects of PEA against audiogenic
seizures in DBA/2 similarly to what was previously observed in
WAG/Rij rats (Citraro et al., 2013b). In this latter model, we de-
monstrated that PEA effects are mediated by CB1 receptors, which
are indirectly activated through the action of PEA on PPAR-α re-
ceptors (Citraro et al., 2013b). However, PEA anticonvulsant effects
might also be related to the enhancement of the action of en-
dogenous AEA (Ben-Shabat et al., 1998; Jonsson et al., 2001; Lam-
bert and Di Marzo, 1999; Petrosino et al., 2010). Therefore, our re-
sults conﬁrm PEA antiepileptic properties while its mechanism
R. Citraro et al. / European Journal of Pharmacology 791 (2016) 523–534532remains to be completely clariﬁed since several systems are prob-
ably involved further than PPAR-α mediated effects such as tran-
sient vanilloid 1 channel (TRPV1) receptors (De Petrocellis et al.,
2001; Ho et al., 2008).
4.4. Conclusions
In conclusion, these results suggest that PEA and cannabinoid
analogues (ACEA and WIN) could be a potential pharmacological
treatment against audiogenic seizures. However, additional studies
are needed to better clarify the antiseizure effects of PPAR-α, in this
and other animal models. Nevertheless, PEA acts through several
mechanisms of action and most of them might contribute to its
anticonvulsant properties. Furthermore, we reported that PEA and
the cannabinomimetics studied are able to potentiate the antiseizure
effects of several AEDs indicating that this drugs and their mechan-
isms of action might be relevant for the development of potentially
new antiepileptic drugs.Conﬂict of interest
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